Pharmacokinetics of tenofovir in haemodialysis

Nephrology Dialysis Transplantation

Volumn 18, Issue 9, 2003, Pages 1931-1933

  Izzedine, Hassane ^a   Launay Vacher, Vincent ^a   Jullien, Vincent ^b   Aymard, Guy ^a   Duvivier, Claudine ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

End stage renal disease; Haemodialysis; Hepatitis B virus; Tenofovir

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; COMORBIDITY; DISTRIBUTION VOLUME; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; HEMODIALYSIS; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; MALE; PRIORITY JOURNAL;

ADENINE; ANTI-HIV AGENTS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; RENAL DIALYSIS;

EID: 0041382710     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg327     Document Type: Article

References (4)

1. Deeks SG, Barditch-Crovo P, Lietman PS et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-(2-(R)-(phosphonomethoxy)propyl)adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998; 42: 2380-2384
2. van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002; 36: 507-508
3. Izzedine H, Launay-Vacher V, Baumelou A, Deray G. An appraisal of anti-retroviral drugs in hemodialysis. Kidney Int 2001; 60: 821-830
4. Braditch-Crovo P, Deeks SG, Collier A et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45: 2733-2739